Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade

International Urology and Nephrology

Volumn 40, Issue 2, 2008, Pages 365-368

  Urakami, Shinji ^a   Shiina, Hiroaki ^a   Sumura, Masahiro ^a   Honda, Satoshi ^a   Wake, Koji ^a   Hiraoka, Takeo ^a   Inoue, Shogo ^a   Ishikawa, Noriyoshi ^a   Igawa, Mikio ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Endocrine therapy; Metastasis; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN; ESTRAMUSTINE;

AGED; ARTICLE; BONE TUMOR; CASE REPORT; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; ESTRAMUSTINE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 52649149750     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-007-9301-z     Document Type: Article

References (10)

1. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168:2444-2450
2. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M (2007) Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51:1252-1258
3. Debes JD, Tindall DJ (2004) Mechanisms of androgenrefractory prostate cancer. N Engl J Med 351:1488-1490
4. Isaacs JT (1989) Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 49:6290-6294
5. Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 109:477-486
6. Labrie F, Candas B, Gomez JL, Cusan L (2002) Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60:115-119
7. Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K (2004) Kurume-Kumamoto Estracyt Study Group: chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109
8. Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P (2007) Long-term followup of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with nonmetastatic high-risk prostate cancer. BJU Int 100:274-280
9. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA (2007) Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 177:1777-1781
10. Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM (2006) Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 24:5408-5413